메뉴 건너뛰기




Volumn 22, Issue 8, 2015, Pages 658-664

A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1

(15)  Tatum, H a   Thuluvath, P J b   Lawitz, E c   Martorell, C d   Demicco, M e   Cohen, S f   Rustgi, V g   Ravendhran, N h   Ghalib, R i   Hanson, J j   Zamparo, J k   Zhao, J k   Cooney, E k   Treitel, M k   Hughes, E k  


Author keywords

all oral regimen; direct acting antiviral; IL28B non CC; NS5B polymerase inhibitor; triple therapy

Indexed keywords

BECLABUVIR; PEGINTERFERON ALPHA2A; PLACEBO; RIBAVIRIN; VIRUS RNA; 8-CYCLOHEXYL-N-((DIMETHYLAMINO)SULFONYL)-1,1A,2,12B-TETRAHYDRO-11-METHOXY-1A-((3-METHYL-3,8-DIAZABICYCLO(3.2.1)OCT-8-YL)CARBONYL)CYCLOPROP(D)INDOLO(2,1-A)(2)BENZAZEPINE-5-CARBOXAMIDE; ALPHA INTERFERON; ANTIVIRUS AGENT; BENZAZEPINE DERIVATIVE; INDOLE DERIVATIVE; NS-5 PROTEIN, HEPATITIS C VIRUS; VIRAL PROTEIN;

EID: 84934827901     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12372     Document Type: Article
Times cited : (17)

References (21)
  • 1
    • 84877730954 scopus 로고    scopus 로고
    • Sofosbuvir for previously untreated chronic hepatitis C infection
    • Lawitz E, Mangia A, Wyles D, et al,. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-1887.
    • (2013) N Engl J Med , vol.368 , pp. 1878-1887
    • Lawitz, E.1    Mangia, A.2    Wyles, D.3
  • 2
    • 84879198467 scopus 로고    scopus 로고
    • Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection in treatment-naive patients: Results from QUEST-1, a phase III trial
    • [abstract 1425]
    • Jacobson I, Dore GJ, Foster GR, et al,. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-1, a phase III trial. J Hepatol 2013; 58 (Suppl. 1): S574 [abstract 1425].
    • (2013) J Hepatol , vol.58 , pp. S574
    • Jacobson, I.1    Dore, G.J.2    Foster, G.R.3
  • 3
    • 84879198467 scopus 로고    scopus 로고
    • Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naive patients: Results from QUEST-2, a phase III trial
    • [abstract 1413]
    • Manns M, Marcellin P, Fred Poordad FP, et al,. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-2, a phase III trial. J Hepatol 2013; 58 (Suppl. 1): S568 [abstract 1413].
    • (2013) J Hepatol , vol.58 , pp. S568
    • Manns, M.1    Marcellin, P.2    Fred Poordad, F.P.3
  • 4
    • 84884223989 scopus 로고    scopus 로고
    • Daclatasvir combined with peginterferon alfa-2a and ribavirin for 12 or 16 weeks in patients with HCV genotype 2 or 3 infection: COMMAND GT2/3 study
    • [abstract 1418]
    • Dore GJ, Lawitz E, Hézode C, et al,. Daclatasvir combined with peginterferon alfa-2a and ribavirin for 12 or 16 weeks in patients with HCV genotype 2 or 3 infection: COMMAND GT2/3 study. J Hepatol 2013; 58 (Suppl. 1): S570-S571 [abstract 1418].
    • (2013) J Hepatol , vol.58 , pp. S570-S571
    • Dore, G.J.1    Lawitz, E.2    Hézode, C.3
  • 5
    • 84932619401 scopus 로고    scopus 로고
    • Randomized study of daclatasvir plus peginterferon alfa-2a and ribavirin for previously untreated chronic hepatitis C
    • Jul 30. [Epub ahead of print] PMID: 25080450
    • Hezode C, Hirschfield G, Ghesquiere W, et al,. Randomized study of daclatasvir plus peginterferon alfa-2a and ribavirin for previously untreated chronic hepatitis C. Gut 2014; Jul 30. doi: 10.1136/gutjnl-2014-307498. [Epub ahead of print] PMID: 25080450
    • (2014) Gut
    • Hezode, C.1    Hirschfield, G.2    Ghesquiere, W.3
  • 6
    • 84892761633 scopus 로고    scopus 로고
    • COSMOS Study: SVR4 results of a once daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype 1 null responders
    • March 3-6, 2013: Atlanta, GA [Abstract 155LB]
    • Lawitz E, Ghalib R, Rodriguez-Torres M,. COSMOS Study: SVR4 results of a once daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype 1 null responders. 20th Conference on Retroviruses and Opportunistic Infections; March 3-6, 2013: Atlanta, GA [Abstract 155LB].
    • 20th Conference on Retroviruses and Opportunistic Infections
    • Lawitz, E.1    Ghalib, R.2    Rodriguez-Torres, M.3
  • 7
    • 84898470261 scopus 로고    scopus 로고
    • American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. (accessed 20 October 2014)
    • American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. Recommendations for Testing, Managing, and Treating Hepatitis C, 2014. Available at: http://www.hcvguidelines.org/full-report-view (accessed 20 October 2014).
    • (2014) Recommendations for Testing, Managing, and Treating Hepatitis C
  • 8
    • 85116185033 scopus 로고    scopus 로고
    • ™ (simeprevir) receives marketing authorisation in the European Union for the treatment of adults with hepatitis C genotype 1 and 4 infection May 16, 2014. (accessed 20 October 2014)
    • ™ (simeprevir) receives marketing authorisation in the European Union for the treatment of adults with hepatitis C genotype 1 and 4 infection. May 16, 2014. Available at: https://www.jnj.com/news/all/OLYSIO-simeprevir-receives-marketing-authorisation-in-the-European-Union-for-the-treatment-of-adults-with-hepatitis-C-genotype-1-and-4-infection (accessed 20 October 2014).
    • Janssen-Cilag International
  • 10
    • 85116185044 scopus 로고    scopus 로고
    • ® (asunaprevir) dual regimen Bristol-Myers Squibb. July 7, 2014. (accessed 20 October 2014)
    • ® (asunaprevir) dual regimen. July 7, 2014. Available at: http://news.bms.com/press-release/japan-approves-first-all-oral-interferon-and-ribavirin-free-hepatitis-c-treatment-dakl (accessed 20 October 2014).
  • 11
    • 84901274668 scopus 로고    scopus 로고
    • Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C virus NS5B polymerase
    • Lemm JA, Liu M, Gentles RG, et al,. Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C virus NS5B polymerase. Antimicrob Agents Chemother 2014; 58: 3485-3495.
    • (2014) Antimicrob Agents Chemother , vol.58 , pp. 3485-3495
    • Lemm, J.A.1    Liu, M.2    Gentles, R.G.3
  • 12
    • 84901289997 scopus 로고    scopus 로고
    • A randomized, placebo-controlled, single ascending dose study of BMS-791325, a hepatitis C virus NS5B polymerase inhibitor, in genotype 1 infection
    • Karen S, Lemm J, Eley T, et al,. A randomized, placebo-controlled, single ascending dose study of BMS-791325, a hepatitis C virus NS5B polymerase inhibitor, in genotype 1 infection. Antimicrob Agents Chemother 2014; 58: 3496-3503.
    • (2014) Antimicrob Agents Chemother , vol.58 , pp. 3496-3503
    • Karen, S.1    Lemm, J.2    Eley, T.3
  • 13
    • 65449152185 scopus 로고    scopus 로고
    • Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection
    • McHutchison JG, Everson GT, Gordon SC, et al,. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-1838.
    • (2009) N Engl J Med , vol.360 , pp. 1827-1838
    • McHutchison, J.G.1    Everson, G.T.2    Gordon, S.C.3
  • 14
    • 79959438789 scopus 로고    scopus 로고
    • Telaprevir for previously untreated chronic hepatitis C virus infection
    • Jacobson IM, McHutchison JG, Dusheiko G, et al,. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
    • (2011) N Engl J Med , vol.364 , pp. 2405-2416
    • Jacobson, I.M.1    McHutchison, J.G.2    Dusheiko, G.3
  • 15
    • 84865494240 scopus 로고    scopus 로고
    • Factors that predict response of patients with hepatitis C virus infection to boceprevir
    • Poordad F, Bronowicki JP, Gordon SC, et al,. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology 2012; 143: 608-618.
    • (2012) Gastroenterology , vol.143 , pp. 608-618
    • Poordad, F.1    Bronowicki, J.P.2    Gordon, S.C.3
  • 16
    • 70349292099 scopus 로고    scopus 로고
    • Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
    • Ge D, Fellay J, Thompson AJ, et al,. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
    • (2009) Nature , vol.461 , pp. 399-401
    • Ge, D.1    Fellay, J.2    Thompson, A.J.3
  • 17
    • 28244461263 scopus 로고    scopus 로고
    • Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase
    • Kukolj G, McGibbon GA, McKercher G, et al,. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase. J Biol Chem 2005; 280: 39260-39267.
    • (2005) J Biol Chem , vol.280 , pp. 39260-39267
    • Kukolj, G.1    McGibbon, G.A.2    McKercher, G.3
  • 18
    • 84866315985 scopus 로고    scopus 로고
    • Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir
    • Pelosi LA, Voss S, Liu M, Gao M, Lemm JA,. Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir. Antimicrob Agents Chemother 2012; 56: 5230-5239.
    • (2012) Antimicrob Agents Chemother , vol.56 , pp. 5230-5239
    • Pelosi, L.A.1    Voss, S.2    Liu, M.3    Gao, M.4    Lemm, J.A.5
  • 19
    • 84890973133 scopus 로고    scopus 로고
    • Randomized study of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 chronic hepatitis C
    • Bronowicki JP, Pol S, Thuluvath PJ, et al,. Randomized study of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 chronic hepatitis C. Antivir Ther 2013; 18: 885-893.
    • (2013) Antivir Ther , vol.18 , pp. 885-893
    • Bronowicki, J.P.1    Pol, S.2    Thuluvath, P.J.3
  • 20
    • 84892761609 scopus 로고    scopus 로고
    • Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection
    • Everson GT, Sims KD, Rodriguez-Torres M, et al,. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology 2014; 146: 420-429.
    • (2014) Gastroenterology , vol.146 , pp. 420-429
    • Everson, G.T.1    Sims, K.D.2    Rodriguez-Torres, M.3
  • 21
    • 84904508283 scopus 로고    scopus 로고
    • Phase 2b study of the interferon-free and ribavirin-free combination of daclatasvir, asunaprevir, and BMS-791325 for 12 weeks in treatment-naive patients with chronic HCV genotype 1 infection
    • November 1-5, 2013: Washington, DC [abstractLB-1]
    • Everson GT, Sims KD, Thuluvath PJ, et al,. Phase 2b study of the interferon-free and ribavirin-free combination of daclatasvir, asunaprevir, and BMS-791325 for 12 weeks in treatment-naive patients with chronic HCV genotype 1 infection. 64th Annual Meeting of the American Association for the Study of Liver Diseases. November 1-5, 2013: Washington, DC [abstractLB-1].
    • 64th Annual Meeting of the American Association for the Study of Liver Diseases
    • Everson, G.T.1    Sims, K.D.2    Thuluvath, P.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.